Zdravlje/Frontier Biopharma has received another Marketing Authorisation in the CEE issued by the Bulgarian Drug Agency for PazoFront® 200mg and 400mg, film-coated tablets (INN: pazopanib). PazoFront’s active substance (pazopanib) is a protein kinase inhibitor that works by preventing the activity of proteins involved in the growth and spread of cancer cells.

Pazopanib is indicated for use in adults to treat:
– kidney cancer that is advanced or has spread to other organs.
– certain forms of soft-tissue sarcoma

PazoFront is a generic version of Novartis’ Votrient which is marketed globally. This marks a proud moment for our company as it expands our presence in the EU and in critical, life-saving medicines.